DR antigens influence graft outcome and HCV recurrence after liver transplantation

Area of Science:

• Immunogenetics
• Transplantation Immunology
• Hepatology

Background:

• Hepatitis C virus (HCV) recurrence post-liver transplantation is common but variable.
• The role of human leukocyte antigen (HLA) -DR antigens in HCV recurrence severity and allograft survival is not fully understood.

Purpose of the Study:

• To investigate the impact of recipient HLA-DR antigens and DR mismatching on HCV recurrence and allograft survival after liver transplantation.

Main Methods:

• Comparison of clinical outcomes in HCV+ liver transplant recipients based on specific DR antigens (DR2, DR3, DR5) versus others.
• Analysis of allograft survival, HCV recurrence rates, liver disease severity, and acute rejection incidence.

Main Results:

• Recipients with DR3 showed reduced allograft survival, higher HCV recurrence, and more severe liver disease.
• Recipients with DR5 demonstrated superior allograft survival, low HCV recurrence, and benign liver disease.
• Zero DR mismatches correlated with better allograft survival, though DR mismatching level did not impact HCV recurrence or severity.

Conclusions:

• Host genetic factors, specifically recipient DR antigens, significantly influence HCV recurrence and allograft outcomes post-liver transplantation.
• Identifying DR antigens can help predict individual patient risk for severe HCV recurrence and inform post-transplant management.